266 related articles for article (PubMed ID: 36761941)
1. The mesenchymal compartment in myelodysplastic syndrome: Its role in the pathogenesis of the disorder and its therapeutic targeting.
Pontikoglou CG; Matheakakis A; Papadaki HA
Front Oncol; 2023; 13():1102495. PubMed ID: 36761941
[TBL] [Abstract][Full Text] [Related]
2. Aging- and Senescence-associated Changes of Mesenchymal Stromal Cells in Myelodysplastic Syndromes.
Mattiucci D; Maurizi G; Leoni P; Poloni A
Cell Transplant; 2018 May; 27(5):754-764. PubMed ID: 29682980
[TBL] [Abstract][Full Text] [Related]
3. Biologic characteristics of bone marrow mesenchymal stem cells in myelodysplastic syndromes.
Kastrinaki MC; Pontikoglou C; Klaus M; Stavroulaki E; Pavlaki K; Papadaki HA
Curr Stem Cell Res Ther; 2011 Jun; 6(2):122-30. PubMed ID: 20528751
[TBL] [Abstract][Full Text] [Related]
4. Mesenchymal Stem and Progenitor Cells in Normal and Dysplastic Hematopoiesis-Masters of Survival and Clonality?
Pleyer L; Valent P; Greil R
Int J Mol Sci; 2016 Jun; 17(7):. PubMed ID: 27355944
[TBL] [Abstract][Full Text] [Related]
5. Bone marrow niche in the myelodysplastic syndromes.
Cogle CR; Saki N; Khodadi E; Li J; Shahjahani M; Azizidoost S
Leuk Res; 2015 Oct; 39(10):1020-7. PubMed ID: 26276090
[TBL] [Abstract][Full Text] [Related]
6. Mesenchymal stromal cells from myelodysplastic and acute myeloid leukemia patients display in vitro reduced proliferative potential and similar capacity to support leukemia cell survival.
Corradi G; Baldazzi C; Očadlíková D; Marconi G; Parisi S; Testoni N; Finelli C; Cavo M; Curti A; Ciciarello M
Stem Cell Res Ther; 2018 Oct; 9(1):271. PubMed ID: 30359303
[TBL] [Abstract][Full Text] [Related]
7. The immunological role of mesenchymal stromal cells in patients with myelodysplastic syndrome.
Zheng L; Zhang L; Guo Y; Xu X; Liu Z; Yan Z; Fu R
Front Immunol; 2022; 13():1078421. PubMed ID: 36569863
[TBL] [Abstract][Full Text] [Related]
8. Inappropriate Notch activity and limited mesenchymal stem cell plasticity in the bone marrow of patients with myelodysplastic syndromes.
Varga G; Kiss J; Várkonyi J; Vas V; Farkas P; Pálóczi K; Uher F
Pathol Oncol Res; 2007; 13(4):311-9. PubMed ID: 18158566
[TBL] [Abstract][Full Text] [Related]
9. Direct modulation of the bone marrow mesenchymal stromal cell compartment by azacitidine enhances healthy hematopoiesis.
Wenk C; Garz AK; Grath S; Huberle C; Witham D; Weickert M; Malinverni R; Niggemeyer J; Kyncl M; Hecker J; Pagel C; Mulholland CB; Müller-Thomas C; Leonhardt H; Bassermann F; Oostendorp RAJ; Metzeler KH; Buschbeck M; Götze KS
Blood Adv; 2018 Dec; 2(23):3447-3461. PubMed ID: 30518537
[TBL] [Abstract][Full Text] [Related]
10. Physician Education: Myelodysplastic Syndrome.
Yoshida Y
Oncologist; 1996; 1(4):284-287. PubMed ID: 10388004
[TBL] [Abstract][Full Text] [Related]
11. Identifying Bone Marrow Microenvironmental Populations in Myelodysplastic Syndrome and Acute Myeloid Leukemia.
Kaszuba CM; Rodems BJ; Sharma S; Franco EI; Ashton JM; Calvi LM; Bajaj J
J Vis Exp; 2023 Nov; (201):. PubMed ID: 38009736
[TBL] [Abstract][Full Text] [Related]
12. MDS cells impair osteolineage differentiation of MSCs via extracellular vesicles to suppress normal hematopoiesis.
Hayashi Y; Kawabata KC; Tanaka Y; Uehara Y; Mabuchi Y; Murakami K; Nishiyama A; Kiryu S; Yoshioka Y; Ota Y; Sugiyama T; Mikami K; Tamura M; Fukushima T; Asada S; Takeda R; Kunisaki Y; Fukuyama T; Yokoyama K; Uchida T; Hagihara M; Ohno N; Usuki K; Tojo A; Katayama Y; Goyama S; Arai F; Tamura T; Nagasawa T; Ochiya T; Inoue D; Kitamura T
Cell Rep; 2022 May; 39(6):110805. PubMed ID: 35545056
[TBL] [Abstract][Full Text] [Related]
13. Luspatercept restores SDF-1-mediated hematopoietic support by MDS-derived mesenchymal stromal cells.
Wobus M; Mies A; Asokan N; Oelschlägel U; Möbus K; Winter S; Cross M; Weidner H; Rauner M; Hofbauer LC; Bornhäuser M; Platzbecker U
Leukemia; 2021 Oct; 35(10):2936-2947. PubMed ID: 34002031
[TBL] [Abstract][Full Text] [Related]
14. The bone marrow stem stromal imbalance--a key feature of disease progression in case of myelodysplastic mouse model.
Das M; Chatterjee S; Basak P; Das P; Pereira JA; Dutta RK; Chaklader M; Chaudhuri S; Law S
J Stem Cells; 2010; 5(2):49-64. PubMed ID: 22049615
[TBL] [Abstract][Full Text] [Related]
15. The microenvironment in myelodysplastic syndromes: Niche-mediated disease initiation and progression.
Li AJ; Calvi LM
Exp Hematol; 2017 Nov; 55():3-18. PubMed ID: 28826860
[TBL] [Abstract][Full Text] [Related]
16. Biology of the bone marrow microenvironment and myelodysplastic syndromes.
Rankin EB; Narla A; Park JK; Lin S; Sakamoto KM
Mol Genet Metab; 2015; 116(1-2):24-8. PubMed ID: 26210353
[TBL] [Abstract][Full Text] [Related]
17. Differential expression of AURKA and AURKB genes in bone marrow stromal mesenchymal cells of myelodysplastic syndrome: correlation with G-banding analysis and FISH.
Oliveira FM; Lucena-Araujo AR; Favarin Mdo C; Palma PV; Rego EM; Falcão RP; Covas DT; Fontes AM
Exp Hematol; 2013 Feb; 41(2):198-208. PubMed ID: 23092930
[TBL] [Abstract][Full Text] [Related]
18. [Senescent Mesenchymal Stem Cells Contribute to Progression of Myelodysplastic Syndromes-Review].
Pang YB; Li WW; Luo JM; Ji J; DU X
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Jun; 26(3):942-946. PubMed ID: 29950248
[TBL] [Abstract][Full Text] [Related]
19. In vitro study of biological characteristics of mesenchymal stem cells in patients with low-risk myelodysplastic syndrome.
Zhang YZ; Zhao DD; Han XP; Jin HJ; Da WM; Yu L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Aug; 16(4):813-8. PubMed ID: 18718067
[TBL] [Abstract][Full Text] [Related]
20. Bone marrow MSCs in MDS: contribution towards dysfunctional hematopoiesis and potential targets for disease response to hypomethylating therapy.
Poon Z; Dighe N; Venkatesan SS; Cheung AMS; Fan X; Bari S; Hota M; Ghosh S; Hwang WYK
Leukemia; 2019 Jun; 33(6):1487-1500. PubMed ID: 30575819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]